Medical Devices - Neuromodulation/Neurostimulation
Strategic Profile
NeuroPace demonstrated 22% revenue growth to $79.9 million in 2024, driven by increased RNS System sales and contributions from a distribution agreement with DIXI Medical. The company operates the only FDA-approved closed-loop neuromodulation system, combining continuous intracranial EEG monitoring and targeted seizure interruption.
Cyborg Score Rationale
The company demonstrated 22% revenue growth in 2024 with $79.9 million in revenues, strong gross margins above 73%, and positive clinical evidence building market adoption. However, as a specialized neurotech player in early commercial stages with limited market penetration, scale challenges and competitive risks remain.
The NAUTILUS trial for drug-resistant idiopathic generalized epilepsy is on track to complete one-year follow-up in March 2025, potentially expanding addressable patient population.
Strong gross margins of 73.9% in 2024 reflect increased production volume, manufacturing efficiencies, and pricing discipline.
Clinical evidence from nearly 600 patients with up to nine years of follow-up demonstrates sustained seizure reductions and quality of life improvements.
Named Competitors
Vagus Nerve Stimulation — Non-responsive neuromodulation for epilepsy
Medical Management — Anti-seizure medications and drug therapies
Recent Developments
(January 2025) Scott Huennekens appointed to Board of Directors with extensive medtech experience